A Novel Clobetasol propionate Spray in The Management of Oral Mucocutaneous Lesions: A Preliminary In-vivo Study

Mucocutaneous disorders often present with oral manifestations, which are recurrent, and painful, and currently have no definitive management options. Corticosteroids are the first-line drugs to be administered. This study aimed to evaluate the efficacy of two formulations; Clobetasol propionate spray 0.05%, Clobetasol propionate spray (0.025%) versus the currently marketed options; Triamcinolone acetonide Oro-mucosal paste (0.1%) and Clobetasol propionate cream (0.05%). In this study, 36 male Sprague Dawley rats were divided into two controls and four treatment groups being Clobetasol propionate spray (0.05%), Clobetasol propionate spray (0.025%) Healing was noted by measuring the ulcer area in each group from days 3-7. Post euthanasia, histopathologic evaluation was done to evaluate healing. No difference was observed between the different treatments (p= 0.079), there was a considerable difference in weight loss across different treatments, with Triamcinolone group showing maximum weight loss when compared to the other groups (p=0.008). Both novel sprays displayed similar clinical results. Clobetasol spray (0.025%) showed better histopathologic signs of healing, followed by Clobetasol spray (0.05%). The formulations have the added advantage of the ease of application to inaccessible areas and thus better healing.